BRAF and melanoma: Despite advances in immune checkpoint blockade immunotherapy and BRAF/MEK-targeted therapies for clinical management of melanoma, it remains critically important to investigate prognostic markers that may more reliably allow for the stratification of patients according to their increased risk of disease recurrence or death, both in the primary neoplasm and in the regional sentinel lymph node, when available.